Fin56

The colonic ECs of mice in the control group were seeded in 6-well plates, infected with adenovirus-packaged sh-IRF7, and screened using puromycin, and colonic ECs with stably silenced IRF7 were obtained after two weeks. pcDNA3.1-IRF7 (oe-IRF7), miR-375-3p inhibitor (miR-inhi), miR-375-3p mimic, and the controls (oe-NC, inhi-NC, and mimic-NC) were brought from GenePharma and transfected into colonic ECs using Lipofectamine 3000 (Invitrogen) based on the manufacturer’s instructions. The transfection efficiency was examined using quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting 48 h after transfection. Cell medium after transfection was added with the ferroptosis inducer FIN56 (5 µM, HY-103087, MedChemExpress, NJ, USA) to establish the in vitro ferroptosis cell model, and the follow-up assays were conducted 12 h after the model establishment.

SCFAs were obtained from Sigma-Aldrich (St. Louis, MO, USA). Erastin, ferrostatin-1, FIN56, necrostatin-1, oxaliplatin, RSL3,pertussis toxin, Entinostat, Ricolinostat, Nicotinamide, SIS17, T5224 and TMP269 were purchased from MedChemExpress (Shanghai, China). DCFH-DA, Hoechst33342, N-acetyl-l-cysteine, propidium iodide, trichostatin A, and Z-vad-FMK were obtained from Beyotime (Shanghai, China). Other cytokines/chemicals included B27 (Invitrogen, Carlsbad, CA, USA), recombinant human EGF and FGF (PeproTech, Rocky Hill, NJ, USA), Cystine (Solarbio, Beijing, China), C11-BODIPY 581/591 dye (Abclonal, Wuhan, China).